Active	Status	Sponsor type	Region	Phase	Filter
3 Active 2 Inactive 5 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other Show only owner-sponsored trials	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
lodapolimab (LY3300054) / Eli Lilly
NCT03099109: A Study of LY3321367 Alone or With LY3300054 in Participants With Advanced Relapsed/Refractory Solid Tumors For advanced r/r solid tumors in combination with LY3300054 Feb 2019 - Feb 2019: For advanced r/r solid tumors in combination with LY3300054	Completed	1a/1b	209	Europe, Japan, US, RoW	LY3321367, LY3300054	Eli Lilly and Company	Solid Tumor	12/19	08/23
NCT02937272: A Study of LY3200882 in Participants With Solid Tumors	Active, not recruiting	1	223	Europe, Canada, Japan, US, RoW	LY3200882, LY3300054, Gemcitabine, nab-Paclitaxel, Cisplatin, Intensity Modulated Radiotherapy	Eli Lilly and Company	Solid Tumor	02/20	08/25
NCT02791334: A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid Tumors	Completed	1	164	Europe, Canada, US, RoW	LY3300054, Ramucirumab, LY3009806, Abemaciclib, LY2835219, Merestinib, LY2801653, LY3321367	Eli Lilly and Company	Solid Tumor, Microsatellite Instability-High (MSI-H) Solid Tumors, Cutaneous Melanoma, Pancreatic Cancer, Breast Cancer (HR+HER2-)	05/20	06/24